T0	Limitation 24366 24370	This
T1	Limitation 24527 24535	Although
T2	Limitation 24804 24806	In
T3	Limitation 25023 25031	Finally,
T4	Limitation 25373 25381	However,
T5	RelevantOutcomeExcluded 24377 24436	did not evaluate atherosclerosis at the carotid bifurcation
T8	DiagnosticCriteria 24819 24893	no attempt was made to select subjects on the basis of inflammatory status
T10	SampleSize 25387 25398	small study
T11	Intervention 25399 25469	cannot thoroughly or systematically evaluate the safety of canakinumab
T12	RelevantOutcomeExcluded 24489 24525	did it quantify plaque lipid content
T6	ValidityOfMeasurement 24624 24675	they offer no direct measure of plaque inflammation
T7	Intervention 25032 25169	we cannot exclude the possibility that the dose of canakinumab was not high enough to generate a maximal effect on atherosclerotic burden
